Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Tao Wang, Lei Gao, Yujie Wang, Wenjun Zhu, Lili Xu, Yang Wang, Wenqin Yue, Gusheng Tang, Li Chen, Jie Chen, Weiping Zhang, Xuejun Yu, Dongge Feng, Jianmin Yang
Abstract
Aim: Autologous hematopoietic stem cell transplantation (ASCT) is the standard-of-care curative treatment for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL), but the relapse rate is usually high. Materials & methods: In this study, we treated 14 RR-DLBCL patients by combining ASCT and anti-CD19 chimeric antigen receptor T-cell therapy. Results: Eleven (78.57%) patients achieved complete or partial remission. Median duration of progression-free survival was 14.82 months (95% CI: 0.00–31.20 months) with 6-month progression-free survival rate of 64.29% (95% CI: 39.18–89.40%). Median overall survival was not achieved, with 1-year overall survival rate of 65.48% (95% CI: 36.00–94.96%). No neurotoxicity was observed. Conclusion: Our study demonstrated safety and feasibility of ASCT and anti-CD19 chimeric antigen receptor T-cell treatment for RR-DLBCL patients.